Comprehensive assessment for novel prostate cancer markers in the prostate-specific antigen era: Focusing on Asians and Asian countries

被引：8

作者：

Okihara, Koji ^{[1
]}

Ochiai, Atsushi ^{[1
]}

Kamoi, Kazumi ^{[1
]}

Fujizuka, Yuji ^{[2
]}

Miki, Tsuneharu ^{[1
]}

Ito, Kazuto ^{[2
]}

机构：

[1] Kyoto Prefectural Univ Med, Dept Urol, Kyoto 6028566, Japan

[2] Gunma Univ, Grad Sch Med, Dept Urol, Maebashi, Gunma 371, Japan

来源：

INTERNATIONAL JOURNAL OF UROLOGY | 2015年 / 22卷 / 04期

关键词：

Asia; proPSA; prostate cancer; PCA3; TMPRSS2:ERG; HEALTH INDEX PHI; MOLECULAR URINE TEST; RADICAL PROSTATECTOMY; GENE FUSIONS; PCA3; MULTICENTER EVALUATION; ACTIVE SURVEILLANCE; ISOFORM P2PSA; TOTAL PSA; JAPANESE;

D O I：

10.1111/iju.12701

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

We reviewed the current evidence for three novel prostate tumor markers (PCA3, TMPRSS2:ERG and proPSA) that have been recently reported predominantly in Western countries. We focus our attention on Asian men in both clinical and basic research studies. There have been no reports on the clinical usefulness of these three markers for Asians living in Western countries. In Asian countries, evidence for the clinical usefulness of PCA3 and proPSA-related indices including Prostate Health Index is being accumulated, mainly in Japan. The process for how a novel marker is approved in the clinical setting is also discussed.

引用

页码：334 / 341

页数：8

共 50 条

[21] Prostate-specific Antigen Testing and Prostate Cancer Screening
Djavan, Bob
Eckersberger, Elisabeth
Finkelstein, Julia
Sadri, Helen
Taneja, Samir S.
Lepor, Herbert
PRIMARY CARE, 2010, 37 (03): : 441 - +
[22] The Role of Prostate-Specific Antigen in Prostate Cancer Screening
Constantin, Traian Vasile
Madan, Victor Lucian
Constantin, Maria-Magdalena
Morariu, Silviu-Horia
Braticevici, Bogdan
REVISTA ROMANA DE MEDICINA DE LABORATOR, 2014, 22 (02): : 275 - 281
[23] The Relationship Between Prostate-Specific Antigen and TNM Classification or Gleason Score in Prostate Cancer Patients With Low Prostate-Specific Antigen Levels
Izumi, Kouji
Ikeda, Hiroko
Maolake, Aerken
Machioka, Kazuaki
Nohara, Takahiro
Narimoto, Kazutaka
Ueno, Satoru
Kadono, Yoshifumi
Kitagawa, Yasuhide
Konaka, Hiroyuki
Mizokami, Atsushi
Namiki, Mikio
PROSTATE, 2015, 75 (10): : 1034 - 1042
[24] The case for prostate cancer screening with prostate-specific antigen
Andriole, Gerald
Djavan, Bob
Fleshner, Neil
Schroder, Fritz
EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (12) : 737 - 745
[25] Prostate-Specific Antigen, Prostate Cancer, and Disorders of Hemostasis
Lippi, Giuseppe
Plebani, Mario
Franchini, Massimo
Guidi, Gian Cesare
Favaloro, Emmanuel J.
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2009, 35 (07): : 654 - 664
[26] Free prostate-specific antigen outperforms total prostate-specific antigen as a predictor of prostate volume in patients without prostate cancer
Avci, Sinan
Onen, Efe
Caglayan, Volkan
Kilic, Metin
Sambel, Murat
Oner, Sedat
ARCHIVIO ITALIANO DI UROLOGIA E ANDROLOGIA, 2020, 92 (01) : 1 - 6
[27] Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
Vickers, Andrew J.
Sjoberg, Daniel D.
Ulmert, David
Vertosick, Emily
Roobol, Monique J.
Thompson, Ian
Heijnsdijk, Eveline A. M.
De Koning, Harry
Atoria-Swartz, Coral
Scardino, Peter T.
Lilja, Hans
BMC MEDICINE, 2014, 12
[28] The use of prostate-specific antigen kinetics to stratify risk in prostate cancer
Presti Jr. J.
Current Urology Reports, 2008, 9 (3) : 226 - 230
[29] Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer
Botchorishvili, George
Matikainen, Mika P.
Lilja, Hans
CURRENT OPINION IN UROLOGY, 2009, 19 (03) : 221 - 226
[30] Prostate cancer in 432 men aged <50 years in the prostate-specific antigen era: a new outlook
Gielchinsky, Ilan
Chang, John
Cusick, Thomas
Delprado, Warick
Quoc Nguyen
Yuen, Carlo
Savdie, Richard
Bohm, Maret
Haynes, Anne-Maree
Scheltema, Matthijs J.
Stricker, Phillip D.
BJU INTERNATIONAL, 2018, 122 : 35 - 41

← 1 2 3 4 5 →